- In late July 2026, Merit Medical Systems reported second-quarter 2026 results showing higher sales of US$418.84 million and net income of US$38.8 million compared with the same period a year earlier, and it is scheduled to present at Canaccord Genuity’s 46th Annual Growth Conference in Boston on August 11, 2026.
- Following the stronger-than-expected first-half performance, Merit raised its full-year 2026 revenue outlook to a range of US$1.63 billion to US$1.64 billion, signaling management’s confidence in execution, profitability, and cash generation.
- We’ll now examine how Merit’s upgraded 2026 revenue and earnings guidance may influence the company’s investment narrative and risk-return profile.
Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
Merit Medical Systems Investment Narrative Recap
To own Merit Medical Systems, you have to believe in its ability to grow as a diversified medtech platform while managing product quality and regulatory complexity. The upgraded 2026 revenue outlook to US$1.631–US$1.643 billion supports the near term catalyst of stronger earnings delivery, but it does not remove key risks around device recalls, reimbursement for WRAPSODY CIE, or exposure to tariffs and China, which could still weigh on execution.
The most relevant recent development here is the July 30 earnings release and guidance increase, which ties directly to the upgraded 2026 targets. Q2 2026 sales of US$418.84 million and net income of US$38.8 million, both higher than a year earlier, underpin management’s confidence. At the same time, ongoing product recalls in hemodialysis and guidewire lines highlight how operational or regulatory setbacks could offset some of the benefit from the stronger first half.
Yet investors should also be aware that product recalls and reimbursement delays could still...
Read the full narrative on Merit Medical Systems (it's free!)
Merit Medical Systems' narrative projects $1.8 billion revenue and $213.7 million earnings by 2029. This requires 6.1% yearly revenue growth and about a $74.4 million earnings increase from $139.3 million today.
Uncover how Merit Medical Systems' forecasts yield a $89.55 fair value, in line with its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue of about US$1.9 billion and earnings of roughly US$223 million by 2029, so this guidance raise may either reinforce their oncology and endoscopy growth story or prompt them to reassess those ambitious targets in light of recall and reimbursement risks.
Explore 2 other fair value estimates on Merit Medical Systems - why the stock might be worth as much as 30% more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Merit Medical Systems research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Merit Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merit Medical Systems' overall financial health at a glance.
Contemplating Other Strategies?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
- The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.
- The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com